Open Orphan (AIM:ORPH) has today launched hVIVO’s COVID-19 Clear Test, an antibody testing service for coronavirus which can return test results to individuals within 48 hours.
The specialist pharmaceutical services company said the antibody tests utilise the Quotient MosaiQ™ system and MosaiQ COVID-19 Antibody Microarray and require a full blood draw.
The group said the hVIVO COVID Clear Test will be offered to large employer groups and channel partners including GP networks, nursing services, health clinics and private hospitals.
Shares in Open Orphan closed at 14.45p on Wednesday afternoon.
Samples will be tested in the company's London laboratory with results returned within 48 hours, this morning’s statement explained.
"hVIVO is a world class company with best in class scientists and facilities,” said Cathal Friel, Executive Chairman of Open Orphan.
He added, “We are very excited to be offering this service and I am confident our work will help large companies and clinics in the UK test their staff and patients to ensure the safety of all employees.”
"Antibody testing is crucial for guidance on immunity, development of vaccinations and potential revaccinations, as well as helping to answer outstanding epidemiological questions about the spread of the virus,” said Franz Walt, Chief Executive of Quotient.
Follow News & Updates from Open Orphan here: